An 8-month-old girl with SCID presented with severe bronchiolitis. She received an HLA-identical sibling BMT without conditioning or GVHD prophylaxis. She deteriorated despite mechanical ventilation but had normal cardiac, hepatic and renal function. ECMO was instituted on day +3 and subsequent improvement was seen concurrently with emergence of CD4 + cells on day +11. She was taken off ECMO on day +18 and suffered a left-sided stroke evidenced by a dense left hemiplegia. She was extubated on day +25 and weaned from supplemental oxygen on day +36 and at day +100 has recovered strength in her extremities. This is the first successful use of ECMO as a bridge to engraftment in a BMT patient. Keywords: BMT; SCID; extracorporeal membrane oxygenation; respiratory synctial virus; influenza HLA-identical sibling transplantation is the treatment of choice for SCID. When undertaken in the neonatal period, it is associated with a 92% survival rate.
HLA-identical sibling transplantation is the treatment of choice for SCID. When undertaken in the neonatal period, it is associated with a 92% survival rate. 1 Bone marrow transplantation complicated by respiratory failure, however, is associated with a 'dismal prognosis'. 2 A study of 348 such BMT patients found a 3% 6-month survival rate. 3 These patients all received conventional mechanical ventilation. We report the first successful use of ECMO in a patient receiving a BMT for SCID.
Case report
The patient is a former full-term female infant with a past history remarkable for thrush and failure to thrive who was transferred to our hospital at 8 months of age with a 1 month history of progressive bronchiolitis. A bronchoalveolar lavage revealed respiratory synctial virus (RSV) and influenza A. She was begun on nebulized ribavirin and oral amantidine. Immunologic evaluation revealed absent immunoglobulins and near complete absence of T and NK cells, a SCID phenotype typically secondary to Jak-3 deficiency. 4 The family history was negative for immunodeficiency, neonatal deaths or consanguinity.
Her only sibling was found to be HLA-identical and she subsequently received 4 × 10 8 mononuclear bone marrow cells per kg. No conditioning or GVHD prophylaxis was used. The following morning her respiratory status deteriorated and she required intubation. Over the ensuing 2 days she continued to deteriorate rapidly. An arterial blood gas on day +3 revealed a pH = 7.09 with a partial pressure of oxygen (Pa O 2 ) = 29 mmHg and partial pressure of carbon dioxide (Pa CO 2 ) = 93 mmHg while receiving 100% fraction of inspired oxygen, a positive end expiratory pressure of 14 cm H 2 O and a peak airway pressure of 45 cm of H 2 O. Her cardiac, hepatic and renal function were all normal.
Venoarterial ECMO was initiated using a 14 French right carotid artery and 12 French right internal jugular vein cannula. Flow was achieved with a Stockert (Sorin Biomedical, Irvine, CA, USA) roller head pump at 100-150 cc/kg/min over the 15 day run. A 0.8 m 2 Avecor oxygenator (Avecor Cardiovascular, Plymouth, MN, USA) was used for the first 5 days and changed to a 1.5 m 2 membrane secondary to inadequate oxygenation and flow. Activated clotting times were kept between 180-200 s. Hemofiltration was initiated on day 8 to promote a negative fluid balance. Isoflurane 0.25-1.0 volume percent was used in line with the ECMO circuit to reduce the requirements for sedation. Neuromuscular blockade was not used and frequent neurological examinations were performed. On day +11 the patient had an absolute lymphocyte count (ALC) of 1056/l of which 37% were CD8
+ vs an ALC of 200/l with 0.1% CD8 + cells at baseline (see Figure 1) . While on ECMO, she had evanescent rashes on her torso. Decannulation occurred on day 15. Within 6 h of decannulation, she was noted to have onset of a dense left hemiplegia and was started on aspirin. Magnetic resonance imaging revealed abnormalities in the right cerebral peduncle and internal capsule consistent with an embolic infarction. She was extubated on day +25 and taken off ribavirin and amantidine the following day. She was weaned off all supplemental oxygen on day +36. On day +38 her total bilirubin rose to 1.9 mg/dl. A liver biopsy subsequently revealed graft-versus-host disease. Her total bilirubin peaked at 4.9 mg/dl and decreased to 1.2 mg/dl (0.02 mmol/l) after treatment with 2 mg/kg/day of prednisone and daily oral cyclosporine.
On day +51 she was transferred to our pediatric rehabilitation facility where she regained strength in her extremities. She was discharged home on day +95. Discussion SCID is a rare immunodeficiency characterized by profound deficiencies of T and B cell function which is uniformly fatal if untreated. The genetic basis for SCID is diverse although the treatment for all forms is bone marrow transplantation. This is the first patient successfully treated with ECMO during BMT.
The effects of ECMO on immune function include activation of the complement cascade, increase in IL-6 and IL-8 and induction of neutropenia. 5 Its effects on lymphocytes are largely unknown, but experience in adults receiving short-term cardiopulmonary bypass suggests that T cell numbers are reduced with reversal of the T helper to T suppressor ratio. 6 Despite this, our patient was able to clear her multiple viral infections and be decannulated, extubated and subsequently weaned off supplemental oxygen entirely. Of note, our patient was female, had only been mechanically ventilated for 1 day prior to ECMO and had peak inspiratory pressures of 45 cm H 2 O. These are all features which have been associated with successful ECMO runs in non-BMT patients infected with RSV. 7, 8 This patient suffered a significant stroke after her right carotid artery was decannulated. Stroke is a known complication during ECMO with an incidence of 2% and a survival rate of 45%. 9 However, it is distinctly unusual following decannulation. Presumably in this patient it was due to ligation of the right common carotid artery and subsequent embolism. Other reported complications that can be encountered after ECMO runs include pulmonary hemorrhage 10 and superior vena cava occlusion. 11 We do not suggest that ECMO is appropriate for all BMT patients who deteriorate despite mechanical ventilation. Nor should this endeavor be undertaken in institutions with little experience in non-neonatal ECMO. Rather, in a patient who has a high likelihood of survival if peritransplant mortality can be avoided, ECMO might be viewed as a bridge to engraftment. Contraindications include multisystem organ failure or a course of mechanical ventilation greater than 6 days. 7, 8 Judicious use of this technology in patients with isolated respiratory failure in centers with established expertise in ECMO, as well as BMT, appears justified.
